Nontoxic, biodegradable, and biocompatible
Particle diameter < 100 nm
Physical stability in blood (no aggregation)
Avoidance of the MPS (no opsonization), prolonged blood circulation time
BBB-targeted and brain delivery (receptor-mediated transcytosis across brain capillary endothelial cells)
Scalable and cost-effective manufacturing process
Amenable to small molecules, peptides, proteins, or nucleic acids
Minimal nanoparticle excipient-induced drug alteration (chemical degradation/alteration, protein denaturation)
Possible modulation of drug release profiles